Grünenthal GroupGrünenthal Group

Grünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration

  • The Joint Venture Collaboration includes a portfolio of 13 brands across six therapeutic areas, with the majority of revenue resulting from pain management medicines
  • The new enterprise will be branded as Grünenthal Meds. Grünenthal owns a 51 percent majority share and intends to acquire the remaining share at the beginning of 2026

Aachen, Germany and Tokyo, Japan, 2 August 2023 – Grünenthal GmbH (CEO: Gabriel Baertschi), a global, science-based, privately-owned pharmaceutical company and Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the successful completion of a deal to enter into a Joint Venture Collaboration for Kyowa Kirin International's established medicines portfolio.

The portfolio comprises 13 brands across six therapeutic areas primarily focused on pain management, including Abstral® and PecFent® for breakthrough cancer pain, Moventig® for opioid-induced constipation, and Adcal-D3® for osteoporosis. All products will continue to be marketed through affiliates in seven major European countries and through a network of partners in various additional territories worldwide.

"Grünenthal is a global leader in pain management. With the addition of this strong portfolio, we will be able to help more patients who suffer from various forms of pain," said Gabriel Baertschi, Chief Executive Officer, Grünenthal.

"The established medicines portfolio has a proud history of delivering life-changing value for patients. Today's announcement now means even more patients, for many years to come, will continue to benefit from the portfolio. We are enormously grateful and proud of our colleagues who have worked tirelessly to make this Joint Venture Collaboration a reality," said Jeremy Morgan, President, Kyowa Kirin International.

Grünenthal owns a 51 percent majority share in the Joint Venture Collaboration, while Kyowa Kirin owns a 49 percent share. Grünenthal intends to fully acquire the remaining 49 percent share via exercising an option at the beginning of 2026.

About Grünenthal Meds

As part of the Joint Venture Collaboration between Grünenthal GmbH and Kyowa Kirin Co., Ltd., a new enterprise has been created to market Kyowa Kirin International's established medicines portfolio, which comprises 13 brands across six therapeutic areas. This enterprise will be branded in all markets as Grünenthal Meds.

The portfolio includes medicines that deliver life-changing value for hundreds of thousands of patients. The portfolio is available in seven major European markets through affiliates and in various additional territories worldwide through a network of partners. Key products in the portfolio include Abstral® and PecFent® (Fentanyl) for breakthrough cancer pain, Moventig® (Naloxegol) for opioid-induced constipation and Adcal-D3® (calcium and vitamin D3) for osteoporosis. Visit to find out more.

About Kyowa Kirin

Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based global specialty pharmaceutical company with a more than 70-year heritage, we apply cutting-edge science, including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork, innovation, and integrity. You can learn more about the business of Kyowa Kirin at:

Kyowa Kirin International is a subsidiary of Kyowa Kirin Co., Ltd.

About Grünenthal

Grünenthal is a global leader in pain management and related diseases. As a science-based, fully-integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2022, Grünenthal employed around 4,400 people and achieved sales of € 1.7 bn.

More information: and Grünenthal Report 2022/23 digital edition (



Kyowa Kirin International
Galabank Business Park
Galashiels, TD1 1QH
United Kingdom

Contacts for Kyowa Kirin International:
Stacey Minton

Contacts for Kyowa Kirin Co., Ltd.:
Hiroki Nakamura

Grünenthal GmbH
Zieglerstr. 6
52078 Aachen

Media Contact:
Florian Dieckmann


About Grünenthal Group

Grünenthal Group
Grünenthal Group

Aachen, Germany

Subscribe to releases from Grünenthal Group

Subscribe to all the latest releases from Grünenthal Group by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Grünenthal Group

Grünenthal’s resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee22.5.2023 11:57:05 EEST | Press release

Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain. Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid therapy, in adults with pain associated with knee osteoarthritis. The U.S. Food and Drug Administration’s Breakthrough Therapy Designation process aims to expedite the development of investigational medicines intended to treat severe conditions and where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on clinically significant endpoints. Aachen, Germany, 22 May 2023 – Grünenthal today announced that its investigational non-opioid medicine resiniferatoxin (RTX), currently undergoing clinical Phase III development, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for pain associated with osteoa

Janneke van der Kamp joins Grünenthal as new Chief Commercial Officer22.11.2022 12:43:05 EET | Press release

Grünenthal today announced that Janneke van der Kamp will join Grünenthal as the new Chief Commercial Officer (CCO), effective 1 March 2023. Janneke van der Kamp joins Grünenthal from Novartis, where she most recently served as Head of Pharma Region Europe. The Dutch native brings broad experience in the pharmaceutical industry from several roles including General Manager, Global Neurosciences Franchise Head and Global Head of Product and Portfolio Strategy for the entire Novartis Pharma portfolio. She worked closely with Research & Development and the Licensing & Acquisitions teams to strengthen the company’s pipeline. Janneke van der Kamp has vast expertise in launching and growing key brands across several disease areas. She is a studied chemist and holds an MBA from INSEAD.

Grünenthal starts Phase III trials for resiniferatoxin in osteoarthritis-related pain18.8.2022 14:20:25 EEST | Press release

Global Phase III programme to enable marketing authorisation in the EU, the US and Japan for an innovativenon-opioid investigational medicine. The programme will be conducted across approx. 200 study sites and include more than 1800 patients suffering from pain associated with osteoarthritis. Globally, more than 300 million patients suffer from osteoarthritis[1]. The global osteoarthritis market is expected to grow to approximately $11.0 billion in 2025[2]. Aachen, Germany – 18 August 2022 –Grünenthal announced today that the company has enrolled the first patient in its global clinical Phase III programme for resiniferatoxin (RTX). RTX is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist, with a well-validated mechanism of action. The discovery of TRPV1 was awarded the Nobel Prize of Physiology or Medicine in 2021. If approved, resiniferatoxin may provide patients with long-lasting pain relief with a favourable safety profile. Grünenthal’s Phase III programme wi